Belly Button (Credit: Canva)
The belly button marks the exact spot where your umbilical cord was once attached—the vital connection that provided oxygen and nutrients in the womb. Once you started breathing, eating, and discharging waste on your own, this cord was no longer needed. What remains is a mark, a reminder of your months in your mother’s womb. However, it often gets ignored as you grow up. And there is nothing wrong with that. Your belly button does not require a special skincare routine, but neglecting its hygiene can lead to a buildup of bacteria, potentially causing a smelly discharge.
But generally, a discharge from your belly button is normal and colourless. According to experts, normal discharge is typically clear or light-coloured, has a slight odor (similar to sweat), and has no pain or redness around the navel.
Experts say that the most common funk you might encounter in your belly button is a bacterial or fungal infection. A study titled
A Jungle in There: Bacteria in Belly Buttons are Highly Diverse, but Predictable published in 2012 in PLOS One Journal states that once rarefied to four hundred reads per sample, bacterial communities from belly buttons proved to be at least as diverse as communities known from other skin studies (on average 67 bacterial phylotypes per belly button).
This occurs due to poor hygiene, excessive sweating, or trapped moisture. Other conditions include navel piercings, cysts, and skin conditions like eczema or psoriasis. People with diabetes are particularly susceptible to fungal infections such as candidiasis if their blood sugar isn't under control, according to a 2019 review in the Journal of Clinical Medicine.
Bacteria and fungi love the dark environment of your belly button. If your belly button is infected, you might notice some redness or swelling. The discharge might look like pus, making your belly button smell bad. If it's a yeast infection, your belly button might also itch.
Belly button or naval piercing, if infected, can lead to severe pain, discolouration, swelling, discharge and pus. It can also cause the skin to appear red, causing delayed or failed healing.
Other common signs include:
Chills or fever
Persistent pain or inflammation
Sensitivity or discomfort when moving
Swelling or tenderness to touch
Credits: SWNS/ NY Post
What began as a typical sports injury for a teenage volleyball player turned into a life-altering medical discovery. McKinnon Galloway, now 33, learned she had a rare genetic condition called neurofibromatosis type 2 (NF2) after a fall during a volleyball match led doctors to perform a routine brain scan.
Galloway was just 16 and playing as a setter on her school volleyball team when she dove for the ball and hit her head on the ground. Concerned about a concussion, doctors ordered an MRI scan. Instead of a simple injury, the scan revealed two tumors in her brain.
Doctors soon confirmed she had neurofibromatosis type 2, a rare genetic disorder that causes tumors to grow on nerves throughout the body.
NF2 occurs when a gene responsible for regulating nerve growth does not function properly. Without this signal telling nerve cells to stop growing, tumors can form along nerves and press on surrounding structures or disrupt nerve function.
When doctors first detected the tumors, they described them as slow growing. But within six months, follow-up scans showed the tumors had doubled in size.
Over the years, the condition progressed. Today Galloway lives with 13 tumors located in different parts of her body. Six are in her spine, three are in her hand, two are in her neck, and two remain in her brain.
To manage the disease, she has undergone several treatments including chemotherapy drugs, radiation therapy, and experimental medical trials. She was prescribed Avastin, a medication originally used to treat breast cancer, in an attempt to slow tumor growth.
At age 21 she also joined a phase-one clinical trial in which researchers tested increasing doses of an experimental drug to evaluate its safety. The trial was eventually stopped for her after she developed adverse reactions.
The most difficult consequences of NF2 have been related to hearing loss caused by tumors affecting auditory nerves. Galloway has undergone four brain surgeries in attempts to remove or control the growth of these tumors.
After the first operations she lost hearing in her right ear. Over the next decade her hearing gradually declined in the left ear as well.
In early 2022, during a family vacation, she woke up unable to hear anything. Initially she believed the television in the room had been muted, but quickly realized she had lost her hearing entirely.
Steroid treatment temporarily restored about 20 percent of hearing in one ear. However, another brain surgery later that year resulted in complete deafness.
The operation, which lasted nearly 10 hours, was intended to remove a tumor threatening her life. Complications during surgery left her hospitalized for weeks and forced her to adapt to a completely silent world.
In the months that followed, Galloway struggled with isolation because she had not yet learned effective ways to communicate without hearing. Over time, assistive technology and digital communication tools helped her reconnect with people around her.
She has since become a content creator and public speaker, using social media to raise awareness about NF2 and educate others about technology that supports deaf individuals.
Her advocacy work also includes supporting research efforts and raising funds for organizations dedicated to neurofibromatosis research.
Despite years of treatments, surgeries and uncertainty, Galloway recently received encouraging news. Her latest medical scan showed stable tumor growth for the first time in four years.
Today she continues to share her experience in hopes of helping other families facing the rare disorder.
“Being diagnosed at 16 meant I still had a childhood,” she said. “Many children with this condition spend those years in hospitals, and they deserve more than that.”
Credit: iStock
While research shows women need more sleep than men due to brain function, hormones, and multitasking, females around the globe are struggling to get enough sleep, according to experts.
A 2016 study by the Sleep Research Centre at the UK’s Loughborough University found that women needed 20 minutes more sleep because of multitasking and performing more complex brain tasks during the day.
But, the American Academy of Sleep Medicine (AASM), revealed that an estimated 30 percent of women fail to get sufficient sleep.
Hormones, mood disorders, and caregiving responsibilities, coupled with professional pressures and stress, are the major reasons driving up insomnia and other sleep issues among women.
“Women around the world face a higher burden of sleep difficulties because their sleep cycles are tightly interlinked with hormonal shifts that occur throughout life,” Dr. Janhvi Siroya Shah, Sleep Specialist from the University of Bern, Switzerland, told HealthandMe.
The gender gap in sleep is real, as revealed by the recent ResMed Global Sleep Survey 2026, which showed that 56 percent of women get a good night's sleep only four days or fewer per week, compared to 50 percent of men.
Women were also 48 percent more likely to report problems falling asleep than men (42 percent). More than 50 percent of women felt waking up not feeling rested for 1-2 nights per week or more, compared to 46 percent of men.
The study flagged stress or anxiety as the biggest barrier to consistent, quality sleep (39 per cent), followed by work-related responsibilities (37 per cent) and household duties (31 per cent) among women.
Speaking to HealthandMe, Dr. Kirti Kadian, from the Department of Pulmonary Critical Care & Sleep Medicine at AIIMS Bhopal, said: “Women experience disproportionate sleep challenges globally, largely because their bodies undergo repeated physiological transitions that influence how sleep is regulated.”
The experts cited the main reasons as
All these factors can alter mood regulation, increase nighttime alertness, and disrupt the architecture of sleep itself.
Dr Kadian said that hormonal fluctuations across the life course -- especially during the menopausal transition -- can affect circadian rhythm, airway stability, pain sensitivity, and the nervous system’s response to stress.
“When these biological changes coincide with external stressors, such as multitasking, emotional labor or caregiving demands, women become far more vulnerable to insomnia and unrefreshing sleep,” Shah said.
The prevalence of sleep disorders increases from about 16–42 percent in pre-menopause to around 39–47 percent in peri-menopause and up to 35–69 percent in post-menopause, indicating that sleep disturbances become more common as women progress through different reproductive stages.
“Declining levels of estrogen and progesterone can disrupt the body’s sleep regulation and trigger symptoms like hot flashes and night sweats, while reduced melatonin may make it harder to fall and stay asleep,” Dr. Kadian explained.
In addition, certain medical conditions that are more common in women, such as thyroid disorders, anemia, and autoimmune diseases, can also negatively affect sleep and overall health.
Poor sleep also significantly affects both physical and mental health, increasing the risk of
The Harvard Medical School suggested that to get a better sleep cycle women should:
Credit: iStock
While early-stage research raised hopes of oral semaglutide (GLP-1 pill) slowing down the progression of Alzheimer’s disease, results of a new large-scale clinical trial have rendered it ineffective.
Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries -- showed that semaglutide led to no significant difference after two years.
The findings, published in the Lancet journal, however, revealed that the popular weight loss drug can lead to significant reductions in several biological markers of Alzheimer’s disease.
Yet, it did not help slow the progression of the neurodegenerative disease, said an international team of researchers, including those from the University of California-San Diego.
"Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease," they said in the paper.
"Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications," the team added.
The studies are the first major phase 3 trials to investigate this possibility in people with early Alzheimer’s disease.
The researchers conducted the trial on about 3,800 patients aged 55-85 years. The patients received either up to 14 mg of oral semaglutide daily or a placebo pill.
After two years, no significant difference was seen in slowing down the cognitive disease's progression in patients taking semaglutide and patients taking the placebo.
"The results of the large evoke(+) trials do not support the efficacy of 14 mg/day of semaglutide given for up to 156 weeks in participants with biomarker-confirmed Alzheimer's disease in the MCI or mild dementia stage," the researchers said.
While “GLP-1 [drugs] have given us so many wonderful results," the trial results are "disappointing,” and “a setback for the field”, endocrinologist Daniel Drucker was quoted as saying to the Scientific American.
Drucker says there are many potential explanations why oral semaglutide didn’t work as hoped. The fatty-acid structure surrounding semaglutide might have prevented it from being able to penetrate certain brain regions, such as the hippocampus, which controls memory and cognitive function.
Alzheimer's disease is a progressive neurodegenerative disease characterised by gradual cognitive and functional decline.
It is one of the most common forms of dementia and mostly affects adults over the age of 65.
Over seven million people in the US, 65 and older, live with the condition, and over 100,00 die from it annually.
The disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate and damage cells responsible for memory.
Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Other signs include:
© 2024 Bennett, Coleman & Company Limited